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Background: Neuromuscular electrical stimulation (NMES) improves muscle performance and
exercise tolerance in chronic obstructive pulmonary disease (COPD) patients. In contrast, no
study has assessed the effect of NMES on dynamic hyperinflation (DH) in COPD. This study
investigated the effect of short-term, high-frequency NMES on DH in patients with COPD.
Methods: Twenty patients were randomly allocated to either a NMES applied bilaterally to the
quadriceps muscles (n Z 11: 8 weeks, 5 days/week, twice/day, 45 min/session) or a control
group (n Z 09). All patients received respiratory physical therapy and stretching exercises.
Free fat mass, pulmonary function, time to exercise tolerance (Tlim), 6-min walk test distance
(6-MWTD), tumor necrosis factor (TNF-a) and b-endorphin levels, Borg dyspnea and leg score
(BDS and BLS) and quality of life by the St. George’s Respiratory Questionnaire score (SGRQ)
were examined before and after the intervention.
Results: Compared with the control group, NMES increased FEV1 and FEV1/FVC, 6-MWD and
Tlim (P < 0.01) and reduced BDS and SGRQ (P < 0.01). Additionally, changes in the Tlim were
positively correlated with respiratory improvements in FEV1 (rhoZ 0.48, P < 0.01). Also, NMES
reduced TNF-a and increased b-endorphin levels, compared with the control group (P < 0.001).thophysiology Research Laboratory, Hospital de Clı´nicas de Porto Alegre, Rua Ramiro Barcelos 2350,
l.: þ55 51 91177267; fax: þ55 51 3359 6332.
ufrgs.br, gaspar.chiappa@gmail.com (G.R. Chiappa).
3 Elsevier Ltd. All rights reserved.
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610 P.J.C. Vieira et al.Conclusion: In summary, 8 weeks of NMES promotes reduction of the perceived sensation of
dyspnea during exercise in patients with COPD. This finding is accompanied by improvements
in FEV1, exercise tolerance and quality of life, and DH. Interestingly, these findings may be
associated with enhanced vasodilatory function and a reduction in inflammatory responses.
Clinical trial registration: NCT01695421.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Patients with chronic obstructive pulmonary disease (COPD)
are characterized by airflow limitation during exercise,
oftentimes resulting in significant exercise intolerance [1].
Although the reduced exercise tolerance in COPD has a
multifactorial origin [2], the progressive increase in oper-
ating lung volumes, secondary to the expiratory flow limi-
tation, dynamic hyperinflation (DH), and consequent
dyspnea, takes on a major role, especially in patients with
advanced disease [3]. Dyspnea is a critical factor in
restricting exercise associated with increased level of
plasma pro-inflammatory cytokines, antioxidant imbalance
and intensive dynamic hyperinflation [4]. In addition, most
patients with COPD present peripheral muscle fatigue [5]
and limited exercise performance [6]. Alterations in skel-
etal muscle are associated with the pathophysiology of
COPD, and linked to marked reductions in oxygen (O2)
transport to limb locomotor muscles [1]. Apparently, O2
transport may be impaired due to deleterious changes in
pulmonary gas exchange resulting in decreased hemoglobin
saturation [7], hyperinflation induced by expiratory flow
limitation and greater respiratory muscle work, all of which
contributing to inspiratory and/or expiratory muscle fa-
tigue [8].
In this context, there is substantial interest in physical
training modalities that do not evoke dyspnea, such as
neuromuscular transcutaneous electrical stimulation
(NMES). NMES involves the application of an electrical
current at a level that induces skeletal muscle contractions
[9]. Application of NMES has been linked to increased
muscle strength, function capacity and health status in
COPD patients [4,10]. Although clinical benefits have been
shown after NMES interventions in chronic disease pop-
ulations [4,11e13], further detailed analyses into the
physiological improvements associated with NMES are
needed. Moreover, and particularly relevant to patients
with COPD, further assessment of whether application of
NMES to peripheral muscles impacts pulmonary function.
Therefore, the present study aimed to evaluate compre-
hensively the clinical and physiological effects of NMES in a
COPD cohort. We reasoned that the NMES could improve
clinical measures linked to the improvement in several
pathophysiological processes associated with COPD.Methods
Patient population
Twenty-one men patients with stable COPD, not engaged in
pulmonary rehabilitation, and who met the criteria definedby the GOLD [14], were recruited in this study. Patients
included in our study did not present cough and sputum
production for most days in three consecutive months in the
last two years or more successive years (chronic bronchitis
diagnosis) [15], presenting moderate to severe airflow
limitation (FEV1 <40% predicted) and a previous history of
exercise intolerance (walked distance by 6-min walk test
[6-MWT] <350 m) [16]. Inclusion criteria were the
following: (1) a diagnosis of COPD with FEV1 <50% predicted
as per the GOLD guidelines and (2) self-reported dyspnea
and/or arm fatigue during at least one activity of daily
living that required arm exercise. Dyspnea and/or physical
activity fatigue were self-reported by the Borg Scale.
Exclusion criteria were as follows: (1) musculoskeletal or
neurologic conditions that might affect exercise perfor-
mance, symptomatic cardiac disease, or previous lung
surgery; (2) an acute exacerbation of COPD that required a
change in pharmacological management within the pre-
ceding 2 months; (3) use of oral corticosteroids; (4) a
change in medication dosage or exacerbation of symptoms
in the preceding 12 weeks; (5) implantable electrical de-
vices; (6) bronqui. Before entering in the study, all patients
had their pulmonary function optimized with long-acting
bronchodilators and corticosteroids. If necessary patients
could also use a short-acting bronchodilator (salbutamol
120 mg/ipratropium 20 mg, Combivent, Boehringer Ingel-
heim GmbH, Ingelheim, Germany). Procedures and poten-
tial risks were clarified in details to the subjects. This study
was conducted in accordance with the amended Declara-
tion of Helsinki. All participants gave written, informed
consent as approved by the Institutional Review Board.
Study design
A prospective double-blind, randomized, pilot study was
conducted to compare the use of NMES to a control inter-
vention. The design of the study is shown in Fig. 1. The
patients were referred from a Private Physical Therapy
Clinic by two investigators who were blind to the order of
patient allocation. Patients were randomly assigned to
either the NMES group (n Z 11) or the control group
(n Z 9). All patients received respiratory physical therapy
(bronchial hygiene techniques such as huffing and assisted
coughing) when indicated by the pulmonary auscultation,
as well as regular stretching exercises (upper limbs, lower
limbs, and back region, during 30 min). Randomization was
performed by the Graphpad StatMate computerized pro-
gram (version 1.01i, San Diego, California, EUA). The NMES
intervention period lasted 60 min, being consistent with
previous investigations [17,18]. Each evaluation consisted
of a two-day protocol including: (1) a quality of life ques-
tionnaire, body composition assessment, pulmonary
Figure 1 The CONSORT. Flow diagram of patients in the study.
NMES in COPD patients 611function tests and an incremental exercise test (day 1); (2)
constant work rate test (CWT) to the limit of tolerance with
electromyography of left vastus lateralis muscle.
NMES intervention
NMES was applied to the bilateral quadriceps with surface
electrodes as previously described [4]. A portable, user
friendly, dual channel NMES stimulator was used (Multi-
current Device, EndoMed 686, Enraf-Nonius B.V., Rotter-
dam, Netherlands, GB 3004). The following training
protocol was chosen in order to minimize the effects of
muscular fatigue: a) symmetrical biphasic square pulsed
current at 50 Hz, b) duty cycle: 2 s on and 18 s off (10%)
during the first week, 5 s on and 25 s off (20%) during the
second week, and 10 s on and 30 s off (33%) thereafter;
and c) pulses of 300e400 ms wide using the highest
tolerable amplitude (15e20 mA at the start of the training
session increasing up to 100 mA). The intensity was
increased until a visible strong muscle contraction
occurred or to the maximum level of toleration. The same
instruction and electrode positions were provided to the
control, although the equipment did not provide any
stimulation current. Patients underwent a series of eval-
uations before and after the 8 week intervention period.
Each evaluation comprised measurements of body
composition, respiratory and exercise variables, as well as
blood drawn.
NMES was applied in each thigh 5 times per week, twice
a day for 8 weeks, lasting 60 min per session. The elec-
trodes were positioned over the motor-point in order to
produce skeletal muscle contractions as a result of intra-
muscular nerve branch activation [19].Outcomes
Body composition, thigh circumference, pulmonary and
respiratory muscle function tests, cardiopulmonary exer-
cise testing, the 6-MWT, TNF-a and b-endorphin level, and
quality of life assessments were obtained. Baseline de-
mographic data including age, gender, body mass index
(BMI), medical history, exercise habits and smoking history
were recorded. Subjects were then asked to rest for 30 min
in the sitting position to achieve a steady cardiopulmonary
status for the following assessments.
Measurements
Body composition and thigh circumference
Fat-free mass (FFM) was measured by bioelectrical
impedance (Bodystat-500, Bodystat Ltd, Douglas, UK).
Impedance measurements were performed on the right
side with subjects supine and with their limbs slightly
apart from the trunk. FFM was calculated by specific
regression equation [20], using height squared divided by
resistance (Ht2/Res) and total body mass and expressed as
a percentage of ideal body weight [4]. All measurements
of the thigh circumference were performed at 14 (C14), 21
(C21) and 28 (C28) cm below the iliac crest iliac crest
while subjects were in a resting state [21]. All anthropo-
metric measurements were taken in accordance with WHO
standards [22].
Pulmonary and respiratory muscle function tests
Spirometric tests were performed using the CPF System
(Medical Graphics-MGC, St. Paul, MN) with airflow being
measured by a calibrated Pitot tube (PreVent,
612 P.J.C. Vieira et al.Pneumotach). The subjects completed at least three
acceptable maximal forced and slow expiratory maneuvers
after 15 min the inhalation of 400 mg of salbutamol via a
metered-dose inhaler [23]. Forced vital capacity (FVC, L),
forced expiratory volume in one second (FEV1, L), FEV1/
FVC, and inspiratory capacity (IC) were measured according
to American Thoracic Society standards [2,23]. Maximal
voluntary ventilation was estimated by multiplying FEV1 by
37.5 [24]. The patients completed at least three slow,
forced expiratory maneuvers, considered acceptable and
reproducible. The predicted values were derived from
those for the Brazilian population [25]. Respiratory muscle
function assessment was performed using a pressure
transducer (MVD-500 V.1.1 Microhard System, Globalmed,
Porto Alegre, Brazil), connected to a system with two uni-
directional valves (DHD Inspiratory Muscle Trainer, Chicago,
Illinois). Maximal static inspiratory (PImax) and expiratory
(PEmax) pressure were determined as described elsewhere
[26]. The highest pressure of six measurements was used
for analysis. Arterial partial pressures for O2 and CO2 were
obtained during visit 1 from samples taken by radial artery
puncture, and analyzed in the ABL 330 system (Radiometer,
Copenhagen, Denmark).
Cardiopulmonary exercise testing
Cardiopulmonary exercise tests were performed on an
electronically braked cycle ergometer (Inbrasport, Porto
Alegre, Brazil) at 60 rpm. The Standard metabolic and
ventilatory responses were measured breath-by-breath
using a calibrated, computer-based system (K4b2,
Cosmed, Rome, Italy). Pulse oximetry (SpO2) was also
assessed during testing (POX 010-340, Mediaid, Torrance,
USA). An incremental exercise test was carried out at
baseline by all subjects to establish individualized work-
loads for the subsequent constant work test (CWT). The
incremental ramp exercise test started with 2-min
unloaded cycling followed by incremental workload ad-
justments of 5e10 watts per min until exhaustion. Gas
exchange variables were averaged every 10 s and peak
oxygen uptake ( _VO2peak) was defined as the highest value
achieved during the test. _VO2 at the first ventilatory
threshold was estimated by the V-slope method as previ-
ously described [27]. Heart rate (HR) was determined
using the ReR intervals from a 12-lead electrocardiogram.
Subjects were also asked to rate their ‘shortness of
breath’ at exercise cessation using the 0e10 Borg’s
category-ratio scale [28]. A CWT test was performed at
baseline and after 8 weeks in all subjects. The CWT to
exercise tolerance (Tlim) was performed without the
administration of long- or short-acting bronchodilators.
The constant power output was chosen to elicit an _VO2
that exceeded the first ventilatory threshold by a value of
60% of the difference between _VO2peak and ventilatory
threshold _VO2 (w80% peak work rate) [29]. Tlim was
defined as the point in time when patients signaled to stop
exercising or could not maintain the required pedaling
rate for 10 s, despite being encouraged by the in-
vestigators. Serial inspiratory capacity (IC) maneuvers
were performed every 2 min during the CWT. Assuming
that total lung capacity (TLC) remains constant during
exercise, IC maneuvers provide an estimate of end-
expiratory lung volume (EELV Z TLC  IC) [30].Electromyography
A four-channel surface electromyography system (Mio-
tool, Miotec Biomedical Device, Porto Alegre, Brazil) was
used to measure muscle activity from the left vastus
lateralis muscle as previously described [31]. Root mean
square values normalized by a previously obtained
maximal voluntary contraction were calculated by a
mathematical routine using Matlab 7.1 software (Math
Works Inc., Natick, MA).
Mechanical efficiency
Gross mechanical efficiency (ME) was calculated as the
ratio of work accomplished min1 (watts converted to
kcal min1) to energy expended min1 (kcal min1). Energy
expenditure min1 (kcal min1) was calculated from _VO2
and the respiratory exchange ratio (RER) as described by
Fornusek and Davis [32].
Six-minute walk test
The maximum distance covered during the 6-MWT was used
to assess submaximal functional capacity [33]. The 6-MWT
was conducted according to ATS guidelines [16]. Dyspnea
and leg effort (Borg scale) as well as SpO2 were assessed at
the beginning and end of the test. Following completion of
the 6-MWT, subjects were asked if they experienced any of
the following symptoms: dyspnea, chest pain, light-
headedness or leg pain.
TNF-a and b-endorphin analysis
A total of ten milliliters of venous blood was taken by the
phlebotomist, 3 ml of which was stored in ethyl-
enediaminetetraacetic acid (EDTA) for analysis of a dif-
ferential white cell count. Seven ml of blood was divided
between an EDTA tube and a lithium heparin (LH)
gel tube. These blood samples were centrifuged and
frozen until assayed. Serum tumor necrosis factor (TNF-a)
and b-endorphin were measured by sandwich enzyme
immunoassay (ELISA) kit (Phoenix Pharmaceuticals,
Inc., USA).
Quality of life questionnaire
The Saint Georges’s Respiratory Questionnaire (SGRQ) [34]
was used to assess the health-related quality of life
(HRQOL). The SGRQ is a self-administered HRQOL measure
containing 50 items and 76 weighted responses divided
into three components: symptoms, activity, and impacts.
The symptoms component contains items addressing the
symptomatology, frequency of cough, sputum production,
wheeze, breathlessness, and the duration and frequency
of breathlessness or wheeze. The activity component ad-
dresses physical activities that either cause or are limited
by breathlessness. The impacts component assesses fac-
tors such as employment, being in control of health,
panic, stigmatization, the need for medication and its side
effects, expectations for health and disturbance of daily
life. Scores ranging from 0 to 100 were calculated for each
component, as well as a total score that summarizes the
responses to all items. A zero score indicates no impair-
ment of HRQOL. The questionnaire takes approximately
10 min to be filled out and has been shown to be repro-
ducible, valid and responsive in both COPD and asthmatic
populations [35].
Table 1 Clinical characteristics of the study population.
NMES
(n Z 11)
Control
(n Z 09)
P value
Demographic/anthropometric
Age, years 56.3  11 56.4  13 0.98
Height (cm) 164.4  89.3 160.5  48.7 0.25
Weight (kg) 75.1  14.1 70.2  14.5 0.46
BMI 27.4  4.3 27.6  6.4 0.74
Fat-free mass
(% ideal weight)
49.14  9.41 51.87  10.92 0.55
COPD disease years 8.2  1.4 8.5  1.8 0.68
Pulmonary function
FEV1, L 0.91  0.33 0.88  0.17 0.11
FEV1, % pred 36.5  10.5 39.6  14.4 0.24
FVC, L 2.13  0.63 2.19  0.63 0.83
FVC, % pred 61.9  20.1 69.7  20.2 0.39
FEV1/FVC 47.5  12.8 56.7  13.6 0.13
FEV1/FVC, % pred 58.6  16.4 68.9  15.6 0.17
MVV, L 38.9  19.8 52.5  24.7 0.18
IC, L 1.99  0.23 2.01  0.32 0.56
IC, % pred 76  12 78  22 0.87
TLC, L 5.88  0.66 5.93  0.43 0.51
TLC, % pred 104  23 106  29 0.52
RV, L 2.88  0.34 2.99  0.49 0.42
RV, % pred 164  34 169  0.44 0.61
DLCO, % pred 50  12 52  17 0.34
Arterial blood gases
PaO2, mm Hg 66  5 68  9 0.77
SaO2, % 92  1.5 93  2.5 0.44
PaCO2, mm Hg 39  3 39.5  6 0.66
Respiratory muscle function
PImax, cm H2O 77.9  24.3 72.2  22.5 0.78
PEmax, cm H2O 60.8  25.8 67.2  28.6 0.66
Peak Flow, ml 191.8  79.8 224.4  106.3 0.78
Incremental ramp exercise test
_VO2 peak, ml min
1 989  245 977  189 0.88
_VCO2 peak, ml min
1 997  187 981  202 0.63
RER peak 1.01  0.03 1.02  0.01 0.69
_VE peak, L 38.3  9.7 34.5  8.5 0.81
_VE peak/MVV, % 101.5  22 103.6  31 0.91
VT peak, L 1.01  0.12 0.98  0.21 0.45
SpO2 peak (%) 92  3 94  2 0.66
Power (watts) 75.5  7.8 70.6  10.7 0.71
Borg dyspnea scores 8 (5e10) 8 (4e9) 0.61
Borg leg effort scores 8 (4e8) 7 (4e8) 0.74
Performance walk
test 6-MWT, m
334.1  89.8 349.9  95.3 0.71
Values are means  standard deviation, except for symptoms
(median and range). Definition of abbreviations: NMES, neuro-
muscular electrical stimulation; BMI, body mass index; FEV1,
forced expiratory volume in 1 s; FVC, forced vital capacity; FEV1/
FVC, FEV1 to FVC ratio; MVV, maximal ventilatory voluntary; IC,
inspiratory capacity; TLC, total lung capacity; RV, residual volume;
DLCO, lung diffusing capacity for carbon monoxide; Pa, arterial
partial pressure; Sa, arterial saturation; PImax and PEmax,
maximal inspiratoryandexpiratorymusclepressure; _VO2Zoxygen
uptake; _VCO2 Z carbon dioxide output; RER Z ratio exchange
ratio; _VE Z minute ventilation; _VE/MVV Z maximal voluntary
ventilation; VTZ tidal volume; SpO2Z oxyhemoglobin saturation
by pulse oximetry; 6-MWT, 6-min walk test. P value represents the
overall comparison between the groups.
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Based on the results of Ngai et al. [36], which examined the
long-term effects of a different electrical stimulation (Acu-
TENS) on FEV1 in COPD patients, with an effect size of 1.51,
power of 0.8 and a value of 0.05, 9 participants per group
were required. Differences between groups at baseline
were assessed by an unpaired Student’s t test; mean dif-
ferences and their 95% confidence intervals are reported
for the main outcomes. In addition, the data following
NMES in patients on group 2 were compared with baseline
values using a two-way, mixed model ANOVA assessing
within (pre vs post) and between-groups (control vs NMES)
effects. Product-moment correlation (Spermann) was used
to define the associations between FEV1 and Tlim. A p-
value <0.05 was considered statistically significant. Sta-
tistical analyses were conducted by using SPSS version 19.0.
All data are presented as mean  SD values.
Results
Flow of participants
Fig. 1 illustrates the flow diagram of patients in the study.
Thirty patients were screened for eligibility. Four patients
did not meet inclusion criteria and 2 declined to partici-
pate. Therefore, 24 patients were randomized. Twelve
patients were randomized to NMES, but 1 patient had an
exacerbation during the first week of intervention period.
Twelve patients were randomized to control, but 3 patients
had an exacerbation during the intervention period.
Therefore, 20 patients completed the study.
At baseline, no significant differences were found be-
tween the groups in anthropometric, pulmonary variables
as well as in respiratory muscle function (Table 1). There
were also no differences in the incremental cardiopulmo-
nary exercise testing results between the groups. Medical
regimen was unchanged throughout the experiments.
Pulmonary and respiratory muscle function
Table 2 shows the results of pulmonary function and res-
piratory muscle function before and after 8 weeks of
treatment. The NMES intervention resulted in significant
improvements in FEV1 (NMES 0.98  0.33 vs 1.12  0.36;
Control 0.96  0.17 vs 0.93  0.27 L; ANOVA, P < 0.001),
FEV1/FVC (NMES 44.1  11.4 vs 53.1  10.8; Control
39.4  9.6 vs 42.1  11.5; ANOVA, P < 0.001), and peak flow
(NMES 191.8  79.8 vs 245.6  86.1; Control 204.4  106.3
vs 212  93.3 ml; ANOVA, P < 0.001). Inspiratory and
expiratory muscle strength increased after the interven-
tion, but there was not a significant interaction effect.
Anthropometric measures
As shown in Table 3, body composition was affected by
NMES program. Fat-free mass (FFM) increased only NMES
(NMES, 32.01  4.75 vs 34.01  4.67%; control, 32.3  5.87
vs 33.1  4.34%; P intra-group <0.01, with no interaction).
Muscle mass (MM) increased byw8% only in the NMES group
Table 2 Pulmonary and respiratory muscle function responses.
NMES Control
Before After Before After
FEV1, L 0.98  0.33 1.12  0.36*yz 0.96  0.17 0.93  0.27
FVC, L 2.10  0.63 2.16  0.62* 2.08  0.66 2.12  0.56
FEV1/FVC, % 44.1  11.4 53.1  10.8*yz 39.4  9.6 42.1  11.5
Peak Flow, ml 191.8  79.8 245.6  86.1*yz 204.4  106.3 212  93.3
PImax, cm H2O 69.9  18.4 77.9  24.3* 72.2  22.5 71.9  18.8
PEmax, cm H2O 52.2  17.4 66.8  15.8* 57.2  18.2 64.1  23.4
Values are means  SD. Definition of abbreviations: NMES, neuromuscular electrical stimulation; FEV1Z forced expiratory volume in 1 s;
FVC Z forced vital capacity; IC Z inspiratory capacity; EELV Z end-expiratory lung volume; PImax Z maximal inspiratory muscle
pressure; PEmaxZmaximal expiratory muscle pressure; *P < 0.05 from before within a given intervention; yP < 0.05 from trough within
a given intervention; zP < 0.05 between-intervention comparison.
614 P.J.C. Vieira et al.(NMES, 49.1  4.55 vs 52.9  5.88 kg; control, 50.2  4.78
vs 50.4  4.88 kg; P intra-group <0.01, with no interac-
tion). Interestingly, thigh circumference significantly
increased of 51.8  7.7 to 53.3  6.9 cm with NMES,
without changes in the control group.Constant work exercise test and the 6-min walk
test
Table 3 shows data from the CWT. The _VO2 (NMES,
989  245 vs 1089  233; control, 977  189 vs
969  1918 ml/min; ANOVA, P < 0.01) and _VE (NMES,
38.3  9.7 vs 46.5  9.2; control, 34.5  8.5 vs 36.9  6.1 L;
ANOVA, P < 0.01) at Tlim increased significantly in theTable 3 Measurements at the time to the limit of tolerance in
NMES
Before After
Body composition
FFM, % 32.01  4.75 34.01
MM, Kg 49.1  4.55 52.9
Thigh circumference
C14, cm 43.1  7.2 44.3
C21, cm 48.5  6.8 49.7
C28, cm 51.8  7.7 53.3
Constant work test
_VO2Tlim, ml min
1 989  245 1089
_VCO2Tlim, ml min
1 997  187 1125
RERTlim 1.01  0.03 1.03
_VETlim, L 38.3  9.7 46.5
Tlim, min 6.9  1.5 9.11
SpO2Tlim 93.2  2.8 97.1
BLETlim 8.6  1.1 7.3
BDSTlim 8.0  1.7 6.2
Mechanical efficiency
Gross ME (%) 19.5  3.5 24.3
6-MWT 359.6  71.3 435.3
Abbreviations: FFM, fat-free mass; MM, muscle mass; thigh circumfere
uptake; _VCO2 Z carbon dioxide output; RER Z ratio exchange ratio
oximetry (oxyhemoglobin saturation); BLES, Borg leg effort; BDS, Bor
min walk test. P value represents the overall comparison between th
within a given treatment; yP < 0.01 between-treatment comparison.NMES group compared with control group. _VCO2 and RER
only augmented when compared with baseline values in the
NMES group. Tlim increased significantly by 32% only in the
NMES group (NMES, 6.9  1.5 vs 9.11  2.4; control,
8.2  3.1 vs 8.4  3.4 min; ANOVA, P < 0.01). Borg leg
effort (NMES, 8.6  1.1 vs 7.3  1.6; control, 7.8  1.6 vs
8.1  1.2; ANOVA, P < 0.01) and Borg dyspnea score (NMES,
8.0  1.7 vs 6.2  1.4; control, 7.3  1.5 vs 7.7  1.4;
ANOVA, P < 0.01) assessed at the end of exercise reduced
significantly following NMES with no change in the control
group. Similarly, mechanical efficiency improved by 24.6%
only in the NMES group (NMES, 19.5  3.5 vs 24.3  4.5;
control, 20.5  5 vs 20.1  4.1; ANOVA, P < 0.01). The 6-
MWT distance significantly increased by nearly 76 m in
the NMES group but not in the control group (NMES,the constant work tests.
Control
4weeks Before After 4weeks
 4.67* 32.3  5.87 33.1  4.34
 5.88* 50.2  4.78 50.4  4.88
 6.7 42.7  7.1 42.7  6.8
 7.1 47.1  8.9 47.4  8.2
 6.9*y 50.1  8.1 50.0  7.8
 233*y 977  189 969  191
 289* 981  202 1003  154
 0.02* 1.02  0.01 1.03  0.01
 9.2*y 34.5  8.5 36.9  6.1
 2.4*y 8.2  3.1 8.4  3.4
 1.2*y 94.6  2.3 94.1  1.8
 1.6*y 7.8  1.6 8.1  1.2
 1.4*y 7.3  1.5 7.7  1.4
 4.5*y 20.5  5 20. 1  4.1
 36.5*y 349.8  95.2 350.6  95.6
nce at 14 cm (C14), 21 cm (C21) and 28 cm (C28); _VO2Z oxygen
; _VE Z minute ventilation; Tlim, exercise tolerance; SpO2, pulse
g dyspnea sensation; Gross ME, mechanical efficiency; 6-MWT, 6-
e groups. Data presented as mean  SD. *P < 0.01 from before
Figure 3 Inspiratory capacity at rest and during exercise
(until the 10th minute) in COPD patients during pre and post
NMES compared with control group. *Differences between the
groups at a given time point. yDifferences related to the pre-
vious time point in a given group.
NMES in COPD patients 615359.6  71.3 vs 435.3  36.5; control, 349.8  95.2 vs
350.6  95.6; ANOVA, P < 0.01).
Association between FEV1 and Tlim
In the NMES group, the improvement in Tlim was signifi-
cantly associated with the increase in FEV1 adjusted for
post-training changes in exercise duration (CWT and 6-
MWT) (rho Z 0.48; P < 0.001) (Fig. 2).
Dynamic hyperinflation responses during exercise
At the 8-week follow-up, inspiratory capacity significantly
increased at 4, 6, 8 and 10 min during the CWT in the NMES
group with no change in the control group (Fig. 3).
Electromyography
Subjects in the NMES group demonstrated a lower sub-
maximal root mean square (RMS) at 8-week follow-up dur-
ing the CWT compared to no change in the control group
(Fig. 4).
TNF-a and b-endorphin levels
NMES resulted in a significant decrease in TNF-a levels
(Fig. 5A, NMES 1.45  0.39 vs 1.05  0.23; Control
1.55  0.33 vs 1.48  0.43 pg/ml; ANOVA, P < 0.001) as well
as a significant increase in b-endorphin levels (Fig. 5B,
NMES, 356  27 vs and 489  34; Control 333  16
vs 345  33; ANOVA, P < 0.001).
Quality of life
The SGRQ domain (NMES, 60  12 vs 44  11; control, 54  9
vs 52  8 after: ANOVA, P < 0.05) and total score (NMES,
48  10 vs 37  11; control, 52  7 vs 50  9: ANOVA,
P < 0.05) improved in the NMES group only (Fig. 6).Figure 2 Scatterplot of the association between changes
(postepre) of FEV1 and Tlim during NMES (closed circles) and
Control group (open squares).Discussion
The primary findings of the present study were that NMES
promoted increases in exercise performance, QOL and pe-
ripheral muscle function, and such changes were accom-
panied by improvements in pulmonary function, markers of
systemic inflammation and pain modulation in COPD pa-
tients. Thus, this study supports clinical benefits of NMES
and extends the knowledge in the NMES-mediated im-
provements in function and QOL in patients with COPD.
Using a different NMES protocol on the stellate ganglion
region, Lau et al. have demonstrated a significant
improvement in FEV1 [37]. In our study, we found similar
effects on FEV1, comparable to bronchodilators therapy
(FEV1 gain 10e15%) [38], with benefits to DH. Other
studies have suggested an association between FEV1 and
reduced residual volume [39]. The effect of NMES on FEV1
does not seem to be directly chemical (i.e. bronchodilators
mechanism) or neural with stimulation in hypothalamic
region reducing airway constriction [40]. In the present
study, the increase of FEV1 may be the result of improve-
ments in peripheral muscle dysfunction, which in turn
contribute to improve FEV1 [41].
There is evidence that NMES attenuates the production
of cardiovascular inflammatory mediators and improves
peripheral endothelium-dependent vasodilatation in
chronic heart failure [42]. In our study, NMES resulted in
decreased TNF-a and increased b-endorphin levels. TNF-a
is considered as an important systemic inflammatory
marker associated with the disease progression in COPD
patients [43]. Therefore, the changes in b-endorphin levels
in patients with COPD after 8 weeks of NMES intervention
may be linked to more systemic benefits. Previous study has
demonstrated that NMES reduces TNF-a and improves pe-
ripheral endothelium-dependent vasodilatation in chronic
heart failure, which could facilitate the blood supply to
active muscles [42]. Although this latter suggested mech-
anism needs to be evaluated in COPD, the hypothesis of
Figure 4 Significant decreases in peripheral muscle fiber activation during constant work rate exercise in response to NMES
(closed circles) compared with Control group (open circles) in patients with chronic obstructive pulmonary disease. RMS Z root
mean square. *P < 0.05.
Figure 5 TNF-a (A) and b-endorphin (B) levels in two groups
before and after the intervention period, (NMES, black bar, and
Control, gray bar). * Two-way repeated-measures ANOVA
(P < 0.001) for group, training and interaction effects.
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tion could be a possible explanation for the increased ex-
ercise tolerance. Additionally, the increased b-endorphin
levels in COPD patients after NMES intervention have
contributed to the rhythm-generating component of the
respiratory centre [44], therefore impacting the respiratory
control.
The FVC reflects the integrity of all components involved
with pulmonary function and is an important surrogate of
cough effectiveness because the peak flow during the
cough is comparable with the mean peak flow during a FVC
manuever [45]. In our study, NMES increased FVC and FEV1.
Apparently, FEV1 is linked to increased strength of the
expiratory musculature and the diameter of upper airways
[46], which helps to reinforce the increase of peak flow and
expiratory muscle strength in our study. This concept is not
novel, especially in the context of demonstrated changed in
respiratory muscle function during traditional exercise
training. In a recent study [47], we showed that aerobic
training results in significant activation of the inspiratory
musculature, similar to the expected effects of inspiratory
muscle training. In part, we believe that these effects
might be due initial inspiratory muscle weakness, which is
afforded the opportunity to improve once expiratory flow
limitations are lessened.
The effect of NMES on peripheral muscle strength has
been described previously [4,21]. In our study, muscle mass
and fat-free mass were changed with NMES. Conversely, Dal
Corso et al. [10] showed no significant changes in muscle
strength with NMES, but an increase in type II and decrease
in type I muscle fibers. However, these changes were not
sufficient to increase muscle strength, which is accordance
with other findings [4]. In our study, we found a significant
increase thigh circumference with NMES as found by Viv-
odtzev et al. [21]. This investigation found an increase of
corrected thigh circumference during application NMES,
suggesting an improvement to neural remodeling because
of the relatively short duration of the interventions (4e6
weeks). However, other investigations did not find changes
in thigh mass evaluated by DEXA [10]. The disparities
Figure 6 SGRQ categorical and total score measured at pre and post NMES and Control. (A) Symptom score; (B) activity score; (C)
impact score; (D) total score. SGRQ Z St. George’s Respiratory Questionnaire. *P < 0.05 within-group comparison and yP < 0.05
between-group comparison.
NMES in COPD patients 617between studies may be attributed to differences in dis-
ease severity and variations in NMES protocols. Apparently,
a difference in parameters of stimulation could influence
the potential for a hypertrophic response. Studies demon-
strating an increase in muscle mass with NMES [21] used
higher intensities (15e90 mA) and lower frequencies
(5e35 Hz) while other studies [10] demonstrating no change
used lower intensities (10e45 mA) and higher frequencies
(50 Hz).
We can only speculate on possible mechanisms related
to the improved exercise tolerance and lung function. In
this regard, NMES has shown to improve cycling mechanical
efficiency as indicated by in our study. Previous studies
have shown a reduced mechanical efficiency seemed to be
associated with an increased work of breathing in COPD
patients [48,49], therefore suggesting the muscle adaption
induced by NMES could at least partially reduce the
breathing demand during exercise.
Apparently, our data are consistent with growing evi-
dence that NMES can be safe and effective in patients with
skeletal muscle dysfunction and exercise intolerance sec-
ondary to systemic chronic diseases. Quittan et al. [18]
have described substantial gains in muscle strength and
exercise tolerance after NMES in patients with congestive
heart failure, which have been confirmed by others [9,50].
These positive effects of NMES are likely to be similar to
those morphological changes described by Maltais et al.[51] in patients with COPD who were submitted to con-
ventional endurance training. Using a comprehensive range
of outcome measures, our study showed a reduction in leg
effort for a submaximal of exercise after NMES training,
which would be consistent with this view. Finally, Vivodtzev
et al. [11] showed that muscle function is associated with a
more favorable muscle anabolic to catabolic balance.
Further morphological studies after NMES training, howev-
er, will be required to test this hypothesis.
Previous studies [4] have demonstrated significant in-
creases in 6-MWT distance after NMES in COPD patients.
Likewise, our results indicate clinically relevant changes in
6-MWT after NMES. We observed an increase of 87 m (95%
CI, 13.16e172.5 m; P < 0.01), which is greater than the
47 m improvement recommended for an intervention to be
of credible clinical significance by ATS [16]. Furthermore,
the increase of 6-MWTwas accompanied by changes in SpO2
(mean increase of 2.3%) and reduction in Borg dyspnea
scores after the NMES intervention, which has been also
shown previously [37]. In contrast, Ngai et al. [52] could not
find reduction in dyspnea score with application of trans-
cutaneous electrical nerve stimulation. It is possible that
the difference between findings may be due to the fact that
COPD patients were in a more stable condition in the study
by Ngai et al. [52], while in other studies [36,37], such as
the current analysis, subjects were considered to have a
higher disease severity.
618 P.J.C. Vieira et al.Some limitations should be addressed in our study. First,
the use of a non-perceptable stimulus as the control
intervention, without a real sham intervention, may have
resulted in ascertainment bias. In order to reduce under-
reporting of clinical improvements in control group, sub-
jects were managed as a group of conventional
physiotherapy, rather than a group non-intervention group.
Second, the limited sample size did not allow us to perform
sub-group analysis that could clarify characteristics possibly
associated with clinical changes. In this regard, we
encourage future research with different sets of patients in
order to clarify those who can derive larger gains with a
NMES program. Third, the lack of post-intervention mea-
surements such as cardiopulmonary exercise testing or
pulmonary tests limited our interpretation of direct in-
dicators of lung hyperinflation and air trapping.
Clinical implications
Electrical stimulation has been shown to produce benefits
in the muscle function of COPD patients [53,54], which in-
dicates that NMES is a potential adjunctive technique
especially for patients who may sustain low metabolic and
ventilatory demands [55]. The present study provides evi-
dence that NMES may improve the exercise tolerance in
COPD non-bronchitic patients. Interestingly, these benefits
may be associated with reduction in dynamic hyperinfla-
tion, inflammatory responses, with concomitant increases
in vasodilatory function.
In summary, the present study shows that a short term,
high frequency, NMES program improves a variety of mea-
sures associated with function, symptomatology, QOL, and
physiological function in COPD patients. As such, this
interventional approach may be an efficacious and feasible
complimentary rehabilitation technique in this chronic
disease population. Future studies should extend the pre-
sent analysis, perhaps testing whether the primary NMES
effects are local (muscular adaptation) or systemic (blood
supply, inflammation, etc).
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